Jacobs & Co’s Royalty Pharma RPRX Stock Holding History

Jacobs & Co’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-8,132	Closed	-$292K	–	125
2023 Q1	$292K	Hold	8,132	–	–	0.04%	111
2022 Q4	$321K	Hold	8,132	–	–	0.04%	110
2022 Q3	$326K	Buy	+8,132	New	+$347K	0.05%	102

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jacobs & Co's RPRX Position: Q2 2023 in Review

Jacobs & Co sold out of Royalty Pharma (RPRX) in Q2 2023, closing a stake of 8,132 shares — an estimated $292K sold.

Jacobs & Co first reported a position in RPRX in Q3 2022 and held it in 3 quarters. The position peaked at $326K in Q3 2022. 325 funds tracked by Wall St. Rank hold RPRX as of Q2 2023.

Jacobs & Co reported no remaining Royalty Pharma position as of Q2 2023 after selling out during the quarter.
Jacobs & Co sold 8,132 Royalty Pharma shares in Q2 2023, an estimated $292K.
Jacobs & Co first reported a position in Royalty Pharma in Q3 2022 and held it in 3 quarters.
Jacobs & Co's Royalty Pharma position peaked at $326K in Q3 2022.
325 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2023.

Based on Jacobs & Co's 13F filing for Q2 2023, filed 11 Jul 2023.